Year-over-year earnings per share growth for the last twelve months: arcutis.com (ARQT)

Brandmark of Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics (ARQT) is overcoming strict FDA oversight through its patents, which has strengthened physician confidence in its dermatological treatments. The GURU.Markets system identifies the quarterly EPS trend vector, where the value of 15.10 serves as the current metric. The issuer's revenues are based on the sale of innovative ointments through pharmacy chains and insurance reimbursements for the treatment of chronic skin diseases.

Arcutis Biotherapeutics, Inc. (ARQT) - Quarterly EPS earnings growth from 07/04/2022 to 11/17/2026

Analytical breakdowns and data insights for company Arcutis Biotherapeutics, Inc. (ARQT)

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Initial company analysis:Arcutis Biotherapeutics, Inc., ARQT
Flagship merchandise of arcutis.com

Arcutis Biotherapeutics (ARQT) maintains a strong market position by developing safe topical formulations of well-known biologics. This metric captures the trend of net income per share between 10-Q quarterly reports. Analyzing the quarter-over-quarter growth of net income per share allows for the identification of hidden costs and the verification of revenue sustainability. The upward trend on the chart confirms the company's ability to pass costs onto consumers due to inelastic demand. This positive trend signals the fundamental efficiency of the business model.

Competitor analysis for Arcutis Biotherapeutics

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Vericel|Year-over-year earnings per share growth for the last 12 months ORKA (orukatx.com)|Year-over-year earnings per share growth for the last twelve months Sanara (SMTI)|DBV Technologies - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Solesence SLSN|journeymedicalcorp.com (DERM) - Earnings per share growth in annualized terms for the last twelve months|FBRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months EMPG|SLGL (sol-gel.com) - Year-over-year net earnings per share growth for the last 12 months|AXIL (AXIL Brands, Inc.) - Year-over-year earnings per share growth for the last twelve months|MDCX (Medicus Pharma Corp) - Quarterly EPS earnings growth|Verrica Pharmaceuticals (VRCA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth